drugset / Trial / NCT04673942
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Timeline
- Start
- 2021-03-29
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
Publications
- Reid TR, Oronsky B, Williams J, Caroen S, Conley A. TGF-beta trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. J Immunother Cancer. 2024 Oct 26;12(10):e009613. doi: 10.1136/jitc-2024-009613.
- Kesari S, Bessudo A, Gastman BR, Conley AP, Villaflor VM, Nabell LM, Madere D, Chacon E, Spencer C, Li L, Larson C, Reid T, Caroen S, Oronsky B, Stirn M, Williams J, Barve MA. BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. Future Oncol. 2022 Sep;18(29):3245-3254. doi: 10.2217/fon-2022-0481. Epub 2022 Aug 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdAPT-001 | Unknown | 1e+12 vg | Other |
| Subject | Nivolumab | Monoclonal antibody | — | — |